Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature
Background: Imatinib is the gold standard in the treatment of chronic myeloid leukemia (CML) patients. Resistance to imatinib is interfering with patients’ responses and their survival. Materials and Methods: We designed a systematic search to find relevant studies by applying appropriate keyword...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2021-04-01
|
| Series: | International Journal of Hematology-Oncology and Stem Cell Research |
| Subjects: | |
| Online Access: | https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1242 |
| _version_ | 1827853644305793024 |
|---|---|
| author | Asiyeh Amouei Nesa Daeian Seyedeh Sana Khezrnia Ava Mansouri Molouk Hadjibabaie |
| author_facet | Asiyeh Amouei Nesa Daeian Seyedeh Sana Khezrnia Ava Mansouri Molouk Hadjibabaie |
| author_sort | Asiyeh Amouei |
| collection | DOAJ |
| description | Background: Imatinib is the gold standard in the treatment of chronic myeloid leukemia (CML) patients. Resistance to imatinib is interfering with patients’ responses and their survival.
Materials and Methods: We designed a systematic search to find relevant studies by applying appropriate keywords in PubMed, Web of Science, Scopus, Ovid, ProQuest, Science Direct, and Google scholar for English studies. We also investigated the aforementioned terms’ correspondence in Magiran, Scientific information database (SID), and Google scholar for Persian articles.
Results: 25 studies were selected for final analysis. Reported hematologic responses from adult studies ranged 86-99% and major molecular responses were estimated in 38.84% of our patients within 12 months of treatment. The most frequently reported adverse drug reactions (ADRs) were edema (n=5 studies, 100%) and fatigue and nausea (n=4 studies, 80%); ADR per capita ratio was 1.46. Only one study informed ADRs in pediatrics demonstrating 93% of patients experienced ADRs after receiving imatinib. Most of the Studies (n=4, 67% from 7 studies) considered BCR/ABL point mutation as the main reason for imatinib resistance. Drug-binding sites and P-loop regions were two common sites for BCR/ABL point mutation.
Conclusion: Imatinib as the first-line treatment for CML has been associated with proper and durable responses in Iranian adults and children CML patients. Moreover, Imatinib life-threatening adverse effects were reported as uncommon. Various responses to modified regimens have been reported in resistant patients; therefore, individualized treatment based on mutation type could be recommended. |
| first_indexed | 2024-03-12T11:08:28Z |
| format | Article |
| id | doaj.art-5337f7065209472fb895f71df0da6044 |
| institution | Directory Open Access Journal |
| issn | 2008-2207 |
| language | English |
| last_indexed | 2024-03-12T11:08:28Z |
| publishDate | 2021-04-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | International Journal of Hematology-Oncology and Stem Cell Research |
| spelling | doaj.art-5337f7065209472fb895f71df0da60442023-09-02T03:17:10ZengTehran University of Medical SciencesInternational Journal of Hematology-Oncology and Stem Cell Research2008-22072021-04-0115210.18502/ijhoscr.v15i2.60421242Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of LiteratureAsiyeh Amouei0Nesa Daeian1Seyedeh Sana Khezrnia2Ava Mansouri3Molouk Hadjibabaie4Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, IranResearch Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, IranResearch Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, IranResearch Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, IranDepartment of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, IranBackground: Imatinib is the gold standard in the treatment of chronic myeloid leukemia (CML) patients. Resistance to imatinib is interfering with patients’ responses and their survival. Materials and Methods: We designed a systematic search to find relevant studies by applying appropriate keywords in PubMed, Web of Science, Scopus, Ovid, ProQuest, Science Direct, and Google scholar for English studies. We also investigated the aforementioned terms’ correspondence in Magiran, Scientific information database (SID), and Google scholar for Persian articles. Results: 25 studies were selected for final analysis. Reported hematologic responses from adult studies ranged 86-99% and major molecular responses were estimated in 38.84% of our patients within 12 months of treatment. The most frequently reported adverse drug reactions (ADRs) were edema (n=5 studies, 100%) and fatigue and nausea (n=4 studies, 80%); ADR per capita ratio was 1.46. Only one study informed ADRs in pediatrics demonstrating 93% of patients experienced ADRs after receiving imatinib. Most of the Studies (n=4, 67% from 7 studies) considered BCR/ABL point mutation as the main reason for imatinib resistance. Drug-binding sites and P-loop regions were two common sites for BCR/ABL point mutation. Conclusion: Imatinib as the first-line treatment for CML has been associated with proper and durable responses in Iranian adults and children CML patients. Moreover, Imatinib life-threatening adverse effects were reported as uncommon. Various responses to modified regimens have been reported in resistant patients; therefore, individualized treatment based on mutation type could be recommended.https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1242Imatinib mesylate; Treatment outcome; Antineoplastic agent resistance; Chronic myeloid leukemia; Adverse drug event |
| spellingShingle | Asiyeh Amouei Nesa Daeian Seyedeh Sana Khezrnia Ava Mansouri Molouk Hadjibabaie Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature International Journal of Hematology-Oncology and Stem Cell Research Imatinib mesylate; Treatment outcome; Antineoplastic agent resistance; Chronic myeloid leukemia; Adverse drug event |
| title | Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature |
| title_full | Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature |
| title_fullStr | Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature |
| title_full_unstemmed | Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature |
| title_short | Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature |
| title_sort | imatinib efficacy safety and resistance in iranian patients with chronic myeloid leukemia a review of literature |
| topic | Imatinib mesylate; Treatment outcome; Antineoplastic agent resistance; Chronic myeloid leukemia; Adverse drug event |
| url | https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1242 |
| work_keys_str_mv | AT asiyehamouei imatinibefficacysafetyandresistanceiniranianpatientswithchronicmyeloidleukemiaareviewofliterature AT nesadaeian imatinibefficacysafetyandresistanceiniranianpatientswithchronicmyeloidleukemiaareviewofliterature AT seyedehsanakhezrnia imatinibefficacysafetyandresistanceiniranianpatientswithchronicmyeloidleukemiaareviewofliterature AT avamansouri imatinibefficacysafetyandresistanceiniranianpatientswithchronicmyeloidleukemiaareviewofliterature AT moloukhadjibabaie imatinibefficacysafetyandresistanceiniranianpatientswithchronicmyeloidleukemiaareviewofliterature |